http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107325048-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c4423185f79003e8f9b981e29323454a
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4188
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-22
filingDate 2010-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88c338179a6bd1fc22d5051e0b1d56d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdf0e7f2d99c5cee10121012ca739e18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1e34dd5bf194586128d9acdc987caa3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60d6e1f44af1213ee20f5fbc6b6b332f
publicationDate 2017-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-107325048-A
titleOfInvention Methods of Using c-Met Modulators
abstract Described is a method of treating cancer by administering a compound of formula (I) (Formula I), or a pharmaceutically acceptable salt or solvate thereof in combination with other cancer treatments, wherein R is halo ; R is halo and Q is CH or N.
priorityDate 2009-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010083414-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005030140-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009136663-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009096435-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419497026
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25102847
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410918632

Total number of triples: 38.